✦ LIBER ✦

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

✍ Scribed by Leonardi, Craig; Matheson, Robert; Zachariae, Claus; Cameron, Gregory; Li, Linda; Edson-Heredia, Emily; Braun, Daniel; Banerjee, Subhashis

Book ID: 125547363
Publisher: Massachusetts Medical Society
Year: 2012
Tongue: English
Weight: 710 KB
Volume: 366
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa1109997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Brodalumab and ixekizumab, anti-interleu

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal : ORIGINAL ARTICLE: Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181–9.ORIGINAL ARTICLE: Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190–9.

✍ Ph. I. Spuls; L. Hooft 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Safety profile of ixekizumab, an anti–IL

Safety profile of ixekizumab, an anti–IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Response to brodalumab and ixekizumab, a

Response to brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal

✍ C. Leonardi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Results after at least 52 weeks of open

Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Safety and Efficacy of ABT-874, a Fully

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

✍ Kimball, Alexa B. 📂 Article 📅 2008 🏛 American Medical Association 🌐 English ⚖ 157 KB

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB